Current Report Filing (8-k)
November 15 2019 - 9:41AM
Edgar (US Regulatory)
UNITED STATES
|
SECURITIES AND EXCHANGE COMMISSION
|
Washington, DC 20549
|
|
FORM 8-K
|
CURRENT REPORT Pursuant
|
to Section 13 or 15(d) of the
|
Securities Exchange Act of 1934
|
|
Date of report (Date of earliest event reported): November 15, 2019
|
Bionik
Laboratories Corp.
(Exact Name
of Registrant as Specified in Its Charter)
Delaware
|
|
000-54717
|
|
27-1340346
|
(State or Other Jurisdiction of Incorporation or Organization)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
483 Bay Street, N105
Toronto, ON
|
|
M5G 2C9
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code: (416) 640-7887
(Former Name
or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company ¨
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol
|
Name
of each exchange on which registered
|
Not applicable
|
Not applicable
|
Not applicable
|
|
Item 7.01
|
Regulation FD Disclosure.
|
On November 15, 2019, Bionik Laboratories
Corp. (the “Company”) issued a press release announcing financial results for the second quarter of fiscal year 2020,
ended September 30, 2019.
A copy of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including
Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will
not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: November 15, 2019
|
BIONIK LABORATORIES CORP.
|
|
|
|
|
By:
|
/s/ Leslie Markow
|
|
Name:
|
Leslie Markow
|
|
Title:
|
Chief Financial Officer
|
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionik Laboratories (CE) (USOTC:BNKL)
Historical Stock Chart
From Jul 2023 to Jul 2024